AstraZeneca, MedImmune and Ethris to develop mRNA treatments for respiratory diseases

AstraZeneca, along with its global biologics research and development unit MedImmune, and German biotech Ethris have entered a strategic research collaboration to develop stabilised non-immunogenic modified messenger ribonucleic acid (mRNA) therapies …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news